Early drug and anti ‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy

ConclusionsInfliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL‐eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients.

Source: Alimentary Pharmacology and Therapeutics - November 10, 2017 Category: Drugs & Pharmacology Authors: H. Bar ‐Yoseph, N. Levhar, L. Selinger, U. Manor, M. Yavzori, O. Picard, E. Fudim, U. Kopylov, R. Eliakim, S. Ben‐Horin, Y. Chowers, B. Ungar Tags: ORIGINAL ARTICLE Source Type: research